Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-10-24
2006-10-24
Shameem, Golam M. M. (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C548S146000, C548S200000, C548S201000
Reexamination Certificate
active
07126004
ABSTRACT:
The present invention relates to novel thiazoline acids and derivatives thereof useful as chelators of trivalent metals in therapeutic applications. For example, the thiazoline acid derivatives are useful in diagnosing and treating pathological conditions associated with an excess of trivalent metals in humans and animals.
REFERENCES:
patent: 3274207 (1966-09-01), Kollonitsch et al.
patent: 3809754 (1974-05-01), Bertrand
patent: 3882110 (1975-05-01), Clemence et al.
patent: 4367233 (1983-01-01), Clark et al.
patent: 4406905 (1983-09-01), Zähner et al.
patent: 4457935 (1984-07-01), Iwao et al.
patent: 4457936 (1984-07-01), Draeger et al.
patent: 4558059 (1985-12-01), Kawasaki et al.
patent: 4736060 (1988-04-01), Tomuro et al.
patent: 4775675 (1988-10-01), Györgydéak et al.
patent: 4902700 (1990-02-01), Hayasi et al.
patent: 4914208 (1990-04-01), Jakob et al.
patent: 5084083 (1992-01-01), Lewis et al.
patent: 5106992 (1992-04-01), Magnin et al.
patent: 5169858 (1992-12-01), Rubin
patent: 5182402 (1993-01-01), Lewis et al.
patent: 5192781 (1993-03-01), Bru-Magniez et al.
patent: 5385922 (1995-01-01), Bron et al.
patent: 5393777 (1995-02-01), Crosa
patent: 5442073 (1995-08-01), Eicken et al.
patent: 5614520 (1997-03-01), Kondo et al.
patent: 5840739 (1998-11-01), Bergeron, Jr.
patent: 6080764 (2000-06-01), Chihiro et al.
patent: 6083966 (2000-07-01), Bergeron, Jr.
patent: 6147070 (2000-11-01), Facchini
patent: 6159983 (2000-12-01), Bergeron, Jr.
patent: 6372912 (2002-04-01), Döring et al.
patent: 6437143 (2002-08-01), Moinet et al.
patent: 6521652 (2003-02-01), Bergeron
patent: 6525080 (2003-02-01), Bergeron
patent: 6559315 (2003-05-01), Bergeron, Jr.
patent: 2002/0049316 (2002-04-01), Halbert et al.
patent: 2245 560 (1974-03-01), None
patent: 30 02 989 (1981-07-01), None
patent: 0214101 (1987-03-01), None
patent: 0214933 (1987-03-01), None
patent: 0513379 (1992-11-01), None
patent: 2 247 243 (1975-05-01), None
patent: 1292 170 (1972-10-01), None
patent: 1382887 (1975-05-01), None
patent: WO94/11367 (1994-05-01), None
patent: WO97/36885 (1997-10-01), None
patent: WO 99/53039 (1999-10-01), None
patent: WO 00/16763 (2000-03-01), None
patent: WO 01/27119 (2001-04-01), None
Kishore et al (1977): STN International CAPLUS database, Columbus (Ohio), Accession No. 1977 : 568396.
Abstract for Accession No. 80:146142 from Chemical Abstract Database.
Abstract for Accession No. 83:206330 from Chemical Abstract Database.
Bergeron, “Iron: A Controlling Nutrient in Proliferative Processes,”Trends in Biochem. Sci., 11:133-136 (1986).
Bergeron, et al., “Synthesis and Biological Evaluation of Hydroxamate-Based Iron Chelators,”J. Med. Chem., 34:3182-3187 (1991).
Bergeron, et al., “A Comparison of the Iron-Clearing Properties of 1,2-Dimethyl-3-Hydroxypyrid-4-One 1,2-Diethyl-3-Hydroxypyrid-4-One and Deferoxamine,”Blood, 79:1882-1890(1992).
Bergeron, et al., “The Desferrithiocin Pharmacophore,”J. Med. Chem., 34: 1411-1417 (1994).
Bickel, et al., “Metabolic Properties of Actinomycetes. Ferrioxamine B,”Helv. Chim. Acta, 43:2129-2138 (1960).
Brittenham, “Pyridoxal Isonicotinoyl Hydrazone: An Effective Iron-Chelator After Oral Administration,”Semin. Hematol., 27:112-116 (1990).
Finch, et al., “Ferrokinetics in Man,”Medicine(Baltimore), 49:17-53 (1970).
Finch, et al., “Perspectives in Iron Metabolism,”N. Engl. J. Med., 306:1520-1528 (1982).
Finch, et al., “Iron Metabolism,”Clin. Physiol. Biochem., 4:5-10 (1986).
Ganguly, P.K., and Gupta, B.M., “Antiviral Activity of Isoquinolines Carbazoles and Other Miscellaneous Synthetic Chemicals in Mice,”Indian J. Med. Res., 63(10):1418-1425 (1975).
Grady, et al. “Rhodotorulic Acid-Investigation of its Potential as an Iron-Chelating Drug,”J. Pharmacol. Exp. Ther., 209:342-348 (1979).
Grady, et al., “HBED: A Potential Oral Iron Chelator,”Ann. N.Y. Acad. Sci., 612:361-368 (1990).
Guterman, et al., “Feasibility of Enterochelin as an Iron-Chelating Drug: Studies with Human Serum and a Mouse Model System,”Gen. Pharmac., 9:123-127 (1978).
Hallberg, “Bioavailability of Dietary Iron in Man,”Ann. Rev. Nutri., 1:123-147 (1981).
Hoffbrand, “Transfusion Siderosis and Chelation Therapy,”Iron in Biochemistry and Medicine, vol. II, p. 449, (London, 1980).
Kishore, V., et al., “Synthesis of α-Poly-[NC-(2-aryl-Δ2-thiazoline-4-carbonyl)-L-lysines] with Antiviral Activity,”Indian Journal of Chemistry, 15B:255-257(1977).
Kontoghiorghes, et al., “1,2-Dimethyl-3-hydroxypyrid-4-one, an Orally Active Chelator for the Treatment of Iron Overload,”Lancet, 1:1294-1295 (1987).
O'Connell, et al., “The Role of Iron in Ferritin-and Haemosiderin-Mediated Lipid Peroxidation in Liposomes,”Biochem. J., 229:135-139 (1985).
Ponka, et al., “Mobilization of Iron from Reticulocytes Identification of Pyridoxal Isonicotinoyl Hydrazone as a New Iron Chelating Agent,”FEBS Lett., 97:317-321 (1979).
Raymond, et al., “Coordination Chemistry and Microbial Iron Transport,”Acc. Chem. Res., 12:183-190 (1979).
Seligman, et al., “Molecular Mechanisms of Iron Metabolism,”The Molecular Basis of Blood Diseases, p. 219 (1987).
Thomas, et al., “Ferritin and Superoxide-Dependent Lipid Peroxidation,”J. Biol. Chem., 260:3275-3280 (1985).
Uhlir, et al., “Specific Sequestering Agents for the Actinides. 21 Synthesis and Initial Biological Testing of Octadentate Mixed Catecholate-hydroxypyridinonate Ligands,”J. Med. Chem., 36:504-509 (1993).
Weintraub, et al., “The Treatment of Hemochromatosis by Phlebotomy,”Med. Clin. N. Am., 50:1579-1590 (1966).
Bergeron, R.J., et al. “Evaluation of Desferrithiocin and its Synthetic Analogues as Orally Effective Iron Chelators”,Journal of Medicinal Chemistry, (1991), 34(7), 2072-2078.
Bergeron, R.J., et al. “Effects of C-4 Stereochemistry and C-4 Hydroxylation on the Iron Clearing Efficiency and Toxicity of Desferrithiocin Analogues”,Journal of Medicinal Chemistry, (1999), 42(13), 2432-2440.
Jalal, M.A.F., et al. “Structure of Anguibactin, a Unique Plasmid-Related Bacterial Siderophore from the Fish Pathogen Vibrio Anguillarum”,Journal of American Chemical Society, (1989), 111(1), 292-296.
Fritsch, G., et al., “Plasmodiumfalciparum: Inhibition in vitro with Lactoferrin, Desferriferrithiocin, and Desferricrocin,”Experimental Parasitology 63:1-9 (1987).
Henry, D.W., “Chemotherapeutic Nitroheterocycles. Derivatives of 5-Nitrothiazole-2-carboxaldehyde and 5-Nitrothiazole-2-carboxylic Acid,”J. Med. Chem. 12(2):303-306 (1969).
Stahel, E., et al., “Iron Chelators: In vitro Inhibitory Effect on the Liver Stage of Rodent and Human Malaria,”Am. J. Trop. Med.-Hyg. 39(3):236-240 (1988).
Ullmanns Encyclopedia of Industrial Chemistry, 5thEdition vol. 14A, “ion exchangers,” pp. 446-456.
Bergeron, R.J., et al., “A Comparative Study of the Iron-Clearing Properties of Desferrithiocin Analogues With Desferrioxamine B in aCebusMonkey Model,”Blood, 81(8):2166-2173, (1993).
Bergeron, R.J., et al., “An Investigation of Desferrithiocin Metabolism,”J. Med. Chem., 37(18):2889-2895, (1994).
Bergeron, R.J., et al., “Desazadesmethyldesferrithiocin Analogues as Orally Effective Iron Chelators,”J. Med. Chem., 42(1):95-108, (1999).
Bergeron, R.J., et al., “Effects of C-4 Stereochemistry and C-4′ Hydroxylation on the Iron Clearing Efficiency and Toxicity of Desferrithiocin Analogues,”J. Med. Chem., 42(13):2432-2440, (1999).
Bergeron, R.J., et al., “Evaluation of the Desferrithiocin Pharmacophore as a Vector for Hydroxamates,”J. Med. Chem., 42(15):2881-2886, (1999).
Bergeron, R.J., et al., “Evaluation of Desferrithiocin and Its Synthetic Analogues as Orally Effective Iron Chelators,”J
Hamilton Brook Smith & Reynolds P.C.
Shameem Golam M. M.
University of Florida Research Foundation Inc.
LandOfFree
Thiazoline acid derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thiazoline acid derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thiazoline acid derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3683661